BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024.
聖迭戈，2024年12月10日（環球新聞）-- BioAtla公司（納斯達克：BCAB），一家專注於開發針對實體腫瘤的條件性活性生物（CAB）抗體療法的全球臨床階段生物技術公司，今天宣佈將在即將於2024年12月13日至15日在華盛頓特區舉行的國際肺癌研究協會（IASLC）基礎與轉化科學熱點會議上進行海報展示。
Presentation Details:
展示詳情：
| Title: | Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC | |
| Authors: | Julia Rotow, Grace K. Dy, Edwin Yau, Elaine Shum, Mariam Alexander, Karen L. Reckamp, Roland Leung, Dariusz M. Kowalski, Jose Fuentes Pradera, Jon Zugazagoitia Fraile, Kyechin Chen, Kartik Aysola, D. Ross Camidge | |
| Poster Number: | PP01.03 | |
| Session Type: | Poster Reception | |
| Session Date and Time: | Saturday, December 14, 2024 from 5:40 P.M. – 6:40 P.M. ET |
| 職務： | 對接受Mecbotamab Vedotin治療的晚期非小細胞肺癌患者中突變KRAS基因型與臨床結果的特徵分析，CAb-AXL-ADC | |
| 作者： | 聚利A Rotow, Grace K. Dy, Edwin Yau, Elaine Shum, Mariam Alexander, Karen L. Reckamp, Roland Leung, Dariusz M. Kowalski, Jose Fuentes Pradera, Jon Zugazagoitia Fraile, Kyechin Chen, Kartik Aysola, D. Ross Camidge | |
| 海報編號： | PP01.03 | |
| 會議類型： | 海報接收 | |
| 會議日期和時間： | 2024年12月14日，星期六，東部時間下午5:40至6:40 |
A copy of the presentation materials can be accessed on the "Publication" section of the Company's website at once the presentation has concluded.
演示材料的副本可在公司網站的「出版」部分訪問，演示結束後即可查看。
About BioAtla, Inc.
關於BioAtla, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company's first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. To learn more about BioAtla, Inc. visit .
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAb technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAb product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAb technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAb product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAb programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAb-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAb-ROR2-ADC). The Phase 2 stage CAb-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company's first dual CAb bispecific t-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAm, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing t cells. To learn more about BioAtla, Inc. visit .
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
Internal Contact:
Richard Waldron
首席財務官
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
外部聯繫方式：
布魯斯·麥克爾
生命科學顧問公司
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。
